In this issue:
Eftilagimod alpha + pembrolizumab for metastatic melanoma
Incidence of new primary cutaneous melanoma in patients with metastatic melanoma treated with ICIs
Pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma
Effect of COXi during ICI treatment in patients with metastatic melanoma and NSCLC
Incidence of TE in patients with melanoma on ICI therapy and its adverse association with survival
Does age matter with anti-PD-1 treatment?
BMI and outcome of metastatic melanoma patients receiving targeted therapy and immunotherapy
Comprehensive analysis of cutaneous and uveal melanoma liver metastases
TIL therapy in metastatic melanoma
Statins may reduce disease recurrence in patients with ulcerated primary melanoma
Please login below to download this issue (PDF)